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ABSTRACT
Introduction A high proportion of people with diabetes 
experience gastrointestinal (GI) symptoms, which may 
be manifestations of diabetic autonomic neuropathy 
(DAN). The current treatment regime is ineffective and 
associated with major side effects. Transcutaneous 
vagal nerve stimulation (tVNS) is a new therapeutic 
option, which has been shown to increase GI motility 
and reduce inflammatory responses. As vagus is the 
main neuronal pathway for extrinsic coordination of GI 
secretion and motility, we hypothesise that tVNS will 
improve DAN- induced GI symptoms in subjects with 
diabetes.
Methods and analysis The DAN- VNS study is a 
randomised multicentre clinical trial investigating the 
effect of short- term, high intensity as well as long- term, 
medium- intensity tVNS on GI symptom alleviation in 120 
subjects with diabetes. The primary outcome consists of 
changes from baseline in subjective ratings of symptom 
severity. Secondary outcomes include changes in gastric 
motility and GI transit time measured by MRI and wireless 
motility capsule. Moreover, cardiovascular and sudomotor 
function, glycaemic control, brain sensory processing and 
presence of low- grade inflammation will be investigated 
as secondary outcome measures. Lastly, 15 responders 
of tVNS treatment will be included in an explorative, 
randomised, cross- over study, in which the acute 
endocrine and metabolic response to short- term tVNS will 
be investigated.
Ethics and dissemination The study has been 
approved by the North Denmark Region Committee 
on Health Research Ethics (N-20190020). Results will 
be published in relevant international peer- reviewed 
journals.
Trial registration number NCT04143269.
INTRODUCTION
Clinical evidence of neuropathy can be 
demonstrated in 40%–50% of people with 
long- term diabetes.1 The pathogenesis of 
diabetic neuropathy is multifactorial and 
includes microvascular dysfunction, meta-
bolic and immune- mediated alterations, as 
well as chronic low- grade inflammation in 
response to long- term exposure to hypergly-
caemia and hypoglycaemia.2 Consequently, 
Strengths and limitations of this study
 ► The prospective double- blinded, sham- controlled 
diabetic autonomic neuropathy (DAN)- vagal nerve 
stimulation (VNS) study was carefully designed by 
leading experts in the field of gastroenterology and 
DAN.
 ► The novel approach will provide needed clini-
cal insight to the effect of transcutaneous VNS on 
gastrointestinal symptoms in diabetes via several 
experimental methods in various relevant organ 
systems.
 ► Patient- reported outcomes regarding symptom se-
verity were chosen as the primary outcome in order 
to put the subjective view of patients in focus.
 ► In order to ensure optimal blinding, a parallel study 
design was chosen, which, in explorative studies, 
may be a weaker design than for example, cross- 
over trials.
 ► Self- administration may be another limitation of the 
study due to inability to verify correct tVNS in regard 
to anatomical stimulation site, stimulation intensity 
and duration.
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progressive and seemingly irreversible damages to both 
peripheral, autonomic and central nerve systems may 
occur.3 Diabetic autonomic neuropathy (DAN) is a 
common, serious and yet under- recognised complication 
to diabetes.4 Up to 40% of people with diabetes experi-
ence gastrointestinal (GI) symptoms, which may be mani-
festations of DAN. The experienced cardinal symptoms 
are nausea, vomiting, early satiety and bloating. More-
over, abdominal pain, diarrhoea, constipation and faecal 
incontinence are also commonly reported.5 6
Currently, management of DAN- related GI symptoms 
relies on dietary interventions, peroral antidiabetics, 
prokinetic agents, surgical procedures7 or gastric elec-
trical stimulation.8 However, these interventions are often 
insufficient and sometimes associated with side effects.9 10 
Consequently, the need for a novel, effective and safe 
treatment option is highly requested by patients as well as 
healthcare professionals.
Projections from the central nervous system coordinate 
and regulate GI functions including motility, enzyme 
secretion and nutrient absorption. The primary extrinsic 
neuronal pathway is the parasympathetic vagus nerve. 
Therefore, DAN- induced vagal impairment, which shifts 
the sympaticovagal balance, is likely to be involved in the 
development of GI symptoms in people with diabetes.4 
Preclinical evidence has demonstrated an association 
between vagal input and basal gastric tone, fundic relax-
ation and gastric contractions, thus demonstrating its 
fundamental role in GI motility.11 12
Transcutaneous vagus nerve stimulation (tVNS) is a 
non- invasive method for activation of the cervical branch 
of the vagus nerve (figure 1). Experimental studies on 
healthy volunteers have shown tVNS to increase frequency 
of antral contractions and gastroduodenal motility 
index.13 Furthermore, preclinical studies have suggested 
that vagal stimulation dampens inflammatory pathways 
Figure 1 Possible physiological functions affected after transcutaneous vagus nerve stimulation
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resulting in reduced levels of proinflammatory cytokines 
such as interleukin 6 (IL-6) and tumour necrosis factor 
(TNF)-α.14 These findings have been reproduced in a 
translational study on healthy volunteers.15 Additionally, 
preliminary clinical studies have demonstrated decreased 
disease activity and lowered levels of acute- phase reactant 
C reactive protein (CRP) in patients with rheumatoid 
arthritis, psoriasis arthritis, and ankylosing spondylitis in 
response to tVNS treatment.16 17 Similarly, a pilot study on 
vagal stimulation of patients with Crohn’s disease showed 
reduced inflammation in response to the treatment.18 
Currently, tVNS is associated with a high safety profile19 
due to predominant stimulation of afferent Aβ-fibres 
within the vagal nerve. Hereby, potential adverse cardiac 
events are limited.20
Taken together, we hypothesise that tVNS treatment 
will improve DAN- induced GI symptoms in people with 
diabetes. We aim to test this hypothesis in a multicentre, 
randomised, double- blinded, sham- controlled, parallel- 
group study; the DAN- VNS study.
METHODS AND ANALYSES
Study design and overview
The DAN- VNS study is composed of four work packages 
(WP) designed to explore the effects of tVNS on DAN- 
induced GI symptoms in people with diabetes (figure 2).
Work package I
In WP- I, the effect of short- term, high- intensity tVNS treat-
ment will be investigated. Participants will be allocated to 
either active or sham treatment and will be instructed to 
self- administer the treatment four times a day for 7 days.
Work package II
Following a wash- out period of minimum 2 weeks, partic-
ipants will continue in WP- II, in which the effect of long- 
term, medium- intensity treatment with tVNS will be 
investigated. Participants will follow the same treatment 
as allocated in WP-1. In WP- II, self- administration of the 
treatment will be performed twice a day for 8 weeks.
Follow-up
A follow- up visit will be conducted 7 days after end of 
WP- II including blood samples and ECG, which will be 
reviewed by a medical doctor in order to ensure partici-
pant safety after cessation of the intervention. Drop- outs 
will likewise be encouraged to participate in a follow- up 
visit after trial discontinuation.
Work package III
In WP- III, the acute endocrine and metabolic response 
to short- term tVNS will be investigated in a randomised, 
explorative, cross- over study. Enriched enrolment will 
include 15 responders from WP- II, defined as those 
having the greatest decrease in GI symptoms in response 
to active tVNS. Participants will be randomised to the 
order of active or sham treatment conducted at two study 
days separated by a wash- out period of minimum 2 weeks. 
During each of the two study days, a semisolid test meal 
will be ingested, and tVNS will be administered by study 
personnel five times (at baseline and every hour there-
after) during a 4 hour session.
Work package IV
In order to provide a comparable baseline dataset, 40 age 
and gender- matched healthy controls will be recruited 
at the site in Aalborg, Denmark for a cross- sectional, 
descriptive study.
Study participants
Participants will be included at three different locations 
in Denmark: at Steno Diabetes Center North Jutland 
(Aalborg), at Steno Diabetes Center Copenhagen and at 
Steno Diabetes Center Aarhus. In total, 120 participants 
will be included for WP- I and WP- II with approximately 
40 at each study site. In contrast, WP- III will be conducted 
in Copenhagen, and WP- IV in Aalborg.
Recruitment and inclusion
Potentially eligible participants will be identified at 
each study site after approval of the treating physician. 
The healthy controls will be recruited locally in Aalborg 
from an established volunteer database or advertise-
ments. Eligible individuals will be provided with both 
oral and written information regarding the study. Before 
consenting to participation, subjects are encouraged 
to consider their decision for 24 hours. Furthermore, 
consent can be withdrawn at any point during the study 
period with no consequences for future treatment. 
Subjects confirm their willingness to participate by signing 
the informed consent form after which they are allowed 
to enter the trial. Screening and inclusion of candidates 
will be performed by a medical doctor.
Inclusion criteria include either a verified diagnosis of 
type 1 diabetes for a minimum of 1 year and stable hyper-
glycaemic medication ensuring that participants as a 
minimum have received the given treatment (long acting 
and fast acting insulin or insulin pump with dosing adjust-
ments according to regimens) for at least 3 months prior 
to study entrance, or a verified diagnosis of type 2 diabetes 
for a minimum of 1 year, for which the patient receives no 
or stable (at least 3 months prior to study entrance) hyper-
glycaemic medication. Additionally, GI symptoms will be 
evaluated using the Gastroparesis Cardinal Symptom 
Index (GCSI) (see online supplemental material 1) and 
the Gastrointestinal Symptom Rating Scale (GSRS) (see 
online supplemental material 2). Inclusion in the study 
require a combined weighted GCSI and GSRS score 
of minimum 2.3. The justification of the cut- off value 
was based on the calculated weighted mean in several 
cohorts of healthy subjects plus one (GCSI) and two 
(GSRS) SDs.21–26 Furthermore, to confirm the diagnosis 
of DAN, participants must have either (1) minimum one 
abnormal cardiac autonomic reflex test (heart rate vari-
ability (HRV) in rest, in response to expiration:inspira-
tion, lying to standing position and Valsalva manoeuvre) 
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assessed with the validated VAGUS device,27 28 or (2) 
decreased electrochemical resistance assessed in both 
hands and feet with the SUDOSCAN device, using a cut- 
off value <50 µS at hand and <70 µS in the feet,29 or (3) 
a autonomic symptom score >16 assessed by the validated 
Composite Autonomic Symptom Score (COMPASS-31) 
questionnaire29–31 (see online supplemental material 3). 
A complete list of inclusion and exclusion criteria can be 
found in table 1. Lists of screened and included subjects 
will be kept at a secure location in order to ensure 
confidentiality.
Participants can be discontinued from the trial based 
on medical judgement or if they are considered non- 
compliant. Drop- outs will be mirror randomised by new 
participants in order to ensure sufficient power of the 
study.
Intervention
The study intervention consists of tVNS, which will be 
applied by a battery- powered handheld tVNS device 
(GammaCore, ElectroCore LLC, Basking Ridge, New 
Jersey, USA). The GammaCore is registered as a class 
Figure 2 Overview of the diabetic autonomic neuropathy (DAN)- vagus nerve stimulation (VNS) study. GI, gastrointestinal.
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IIa medical device, and has been CE marketed (CE 
571753) for the following indications in adults: primary 
headache (migraines, cluster headache, and hemicra-
nias continua) and medication overuse headache.32 The 
GammaCore device provides electrical stimulation of the 
cervical region of the vagal nerve by producing a propri-
etary low‐voltage electrical signal comprising a 5‐kHz sine 
wave burst lasting for 1 millisecond (five sine waves, each 
lasting 200 microseconds). Bursts are repeated once every 
40 ms (25 Hz), generating a 24 V peak voltage and 60 mA 
peak output current. On stimulation, the device is posi-
tioned at the cervical course of the vagal nerve, situated 
anterior to the sternocleidomastoid muscle and lateral to 
the carotid artery. Stimulation is provided through two 
steel contact electrodes, which, prior to use, are covered 
with conductive gel (Sigma gel, Parker Laboratories, 
New Jersey, USA). Based on the manufacturer’s recom-
mendations, each stimulation in the DAN- VNS study will 
consist of two consecutive bilateral tVNS doses, which 
corresponds to 2×120 s. Intensity of the stimulation can 
be adjusted by the user in the range of 1–40 (arbitrary 
units) via the digital user interface. The stimulation has 
been optimised, in regard to intensity (24 V peak voltage 
and 60 mA peak output current), pulse duration (1 ms), 
and frequency (5 kHz), to predominantly target afferent 
Aβ-fibres. Hereby, interference with cardiovascular inner-
vating efferent C- fibres is limited and potential adverse 
effects such as bradycardia and bronchoconstriction are 
limited.20
Participants will be instructed to use the highest toler-
able intensity setting in order to obtain maximum vagal 
stimulation. Placebo intervention will be applied by a 
sham GammaCore device (ElectroCore LLC, Basking 
Ridge, New Jersey, USA), which is identical to the active 
device in regard to appearance and application. In 
contrast to the electrical stimulation provided by the 
active device, the sham device provides a stimulation 
sound in order to mimic the active treatment. However, 
to eliminate the possibility of participants being able to 
distinguish between the active and sham stimulation, a 
parallel study design, in which all subjects remain in their 
allocated treatment group throughout the entire study, 
was chosen for WP- I and WP- II.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age≥18 years Significant GI diseases not related to diabetes
Verified diagnosis of either type 1 or type 2 diabetes for a 
minimum of 1 year and with stable medication
Significant cardiovascular diseases
Weighted composite score of GCSI and GSRS ≥2.3 GI surgery within 3 months prior to study inclusion
One or more of the following: (1) CAN- score ≥1*, (2) 
electrochemical resistance <50 µS in hands or <70 µS in 
feet†, (3) COMPASS-31 score ≥16‡
Swallowing disorders
Ability to read and understand Danish Blood pressure <100/60 or >160/105
Personally signed and dated informed consent documents Clinically significant bradycardia or tachycardia
Willingness and ability to comply with scheduled visits, 
treatment plan, laboratory tests and other trial procedures
Implanted portable electromechanical medical devices 
including pacemaker, defibrillator, cochlear implant and infusion 
pump
  Previous surgery of the vagus nerve
  Active laser treatment for proliferative retinopathy
  Contraindications for MRI§
  Any clinical abnormalities, that in the opinion of the investigator 
may increase the risk associated with trial participation or may 
interfere with the interpretation of the trial results
  Pregnancy or intention to become pregnant or father a child 
during the course of the study
  Participation in other clinical trials less than 3 months prior 
to inclusion, unless such a participation is judged to have no 
influence on the recordings
*Cardiovascular Autonomic Neuropathy measured by VAGUS (procedure elaborated under the sections Outcomes and Experimental 
Procedure; Cardiovascular and Sudomotor Function).
†Measured by the SUDOSCAN device (procedure elaborated under the sections Outcomes and Experimental Procedure; Cardiovascular and 
Sudomotor Function).
‡Composite Autonomic Symptom Score.
§Only relevant for participants included at SDCN.
GCSI, gastroparesis cardinal symptom score; GI, gastrointestinal; GSRS, gastrointestinal symptom rating scale.
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During the instruction session, correct placement of 
the device will be marked on the cervical region with a 
permanent marker. Participants are encouraged to refresh 
these marks at regular intervals in order to ensure tVNS/
sham compliance. Furthermore, before the GammaCore 
is handed out, a thorough instruction of the use of the 
device and of compliance and daily doses will be given to 
ensure that the participants acknowledge the importance 
of receiving sufficient self- administered stimulation. In 
addition, this is emphasised in the handed- out Danish 
version of the user manual, which encourages stimula-
tion within certain time windows, for example, morning 
between 06:00 and 07:00.
tVNS will be applied as an add- on treatment, in the 
sense that any habitual medication of participants will 
be continued without any changes. Habitual medication 
must be stable prior to inclusion in the study. During the 
study period, no new medication must by introduced to 
participants.
In WP- I and II, tVNS/sham treatment will be self- 
administered as two bilateral doses conducted four or 
two times a day, respectively, with approximately six- or 
12 hours intervals. Participants will note time and inten-
sity level of each stimulation or lack of such in a provided 
diary. In WP- III, tVNS/sham treatment will be applied by 
study personnel.
Outcomes and experimental procedures
An overview of outcomes and methods of assessment is 
presented in table 2 and tables 3–5. Experimental proce-
dures are described below.
Patient-reported outcomes
Upper GI symptoms will be evaluated by the Patient 
Assessment of Upper GI Symptom Severity Index, 
which is a validated tool developed for measurement 
of symptom severity in patients with gastroparesis and 
includes the GCSI covering three subgroups: nausea/
vomiting, bloating and postprandial fullness33 (see online 
supplemental material 1). Predominantly lower GI symp-
toms will be evaluated by the GSRS questionnaire, which 
was developed and validated for patients with luminal GI 
symptoms, covering five subgroups: reflux, abdominal 
pain, indigestion, diarrhoea, constipation34 (see online 
supplemental material 2). Additionally, the COMPASS-
3130 will be applied for quantitative self- assessment of 
autonomic dysfunction symptoms (see online supple-
mental material 3).
Cardiovascular and sudomotor function
Several aspects of cardiovascular function will be assessed 
in order to investigate the presence of cardiac autonomic 
neuropathy in participants. (1) Cardiac vagal tone will 
be measured during 5 min of rest using a non- invasive 
ECG monitor (eMotion Faros, Mega Electronics, Kuopio, 
Finland). (2) Cardiovascular reflexes will be evaluated in 
response to three standardised tests: (a) posture change 
(supine to standing), (b) deep breathing respiratory cycle 
and (c) the Valsalva manoeuvre using the Vagus device 
(Medicus Engineering, Aarhus, Denmark). Based on age- 
dependent cut- off values, the device provides a cardiovas-
cular autonomic neuropathy (CAN) score ranging from 
0 to 3, indicating the level of CAN as being either absent, 
borderline or definitive.35 (3) Five days continuous 
Holter monitoring will be applied for extraction of HRV 
measures (time and frequency domain) of study partici-
pants using the ePatch device (BioTelemetry Technology 
Aps, Hørsholm, Denmark). The HRV measurements will 
be performed in accordance with the standards defined 
by The Task Force of the European Society of Cardiology 
and The North American Society of pacing and Electro-
physiology. Additionally, sudomotor function has been 
suggested as an early marker of small fibre neuropathy.36 
The electrochemical reaction mediated by chloride ions 
after stimulation of sweat glands will be assessed in both 
hands and feet by a non- invasive device (SUDOSCAN, 
Impeto Medical, California, San Diego, USA).37
Resting brain electrical activity
Electroencephalography (EEG) will be recorded in resting 
state for 5 min during which the subject is instructed to 
keep the eyes closed. The recording will be conducted 
with 40 electrodes by a direct current amplifier (NuAmp, 
Neuroscan, El Paso, USA). As previously reported by this 
group, resting EEG will be used to model connectivity 
between brain centres as well as to identify dominating 
centres of brain activity.38 The data will be preprocessed 
offline. First, notch filtered from 49 to 51 Hz, followed by 
a bandpass filter from 1 to 70 Hz. Afterwards, time inter-
vals with clear artefacts in the majority of channels due to 
heavy muscle activity, and so on, will be removed along 
with interpolation of channels with abnormal traces or 
high amplitudes. The signal will lastly be re- referenced to 
the average reference before further analysis. The spec-
tral indencies of the data will be analysed using a contin-
uous wavelet analysis using a Morlet wavelet function with 
a bandwidth parameter of 10 Hz and a wavelet centre 
frequency of 1 Hz. Source localisation will be performed 
by the standardised low- resolution brain electromagnetic 
tomography.
Quantitative sensory testing
Sensory function will be assessed by quantitative sensory 
testing. First, pain tolerance threshold to bone and muscle 
pressure will be performed on the tibia bone and quad-
riceps muscle. A handheld pressure algometer (Type 2, 
Somedic Production AB, Sweden), applied at a rate of 
30 kPa/s, will be used. Second, a cold pressor test will be 
applied. Participants will be instructed to immerse the 
left hand in circulating ice- chilled water (2℃) for 120 s or 
until pain becomes intolerable. During the immersion, 
pain intensity will be rated regularly on a visual analogue 
scale. Furthermore, immediately after the hand is with-
drawn from the ice water, a pain test stimulus (quadriceps 
muscle pressure) will be applied, allowing for quantifica-
tion of the conditioned pain modulation capacity, which 
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Table 2 Outcomes and methods of assessment
Work package I
  Primary outcome Methods of assessment
  Patient- reported outcomes of gastrointestinal (GI) symptoms PAGI- SYM and GSRS questionnaire
  Secondary outcomes Methods of assessment
  Cardiovascular and sudomotor function   i) Cardiac vagal tone, ii) Cardiovascular reflexes, iii) Holter 
monitoring, iv) Stimulation of sweat glands in hands and 
feet
  Resting brain electrical activity Electroencephalogram
  Quantitative sensory testing   i) Bone- and muscle pressure ii) Cold pressor test with 
conditioned pain modulation
  Brain function MRI
  GI tract function MRI
  Glycaemic control Continuous glucose monitoring
  Circulating inflammatory biomarkers Multiplex analysis of serum samples
Work package II
  Primary outcome Methods of assessment
  Patient- reported outcomes of GI symptoms PAGI- SYM and GSRS questionnaire
  Secondary outcomes Methods of assessment
  Cardiovascular and sudomotor function   i) Cardiac vagal tone, ii) Cardiovascular reflexes, iii) Holter 
monitoring, iv) Stimulation of sweat glands in hands and 
feet
  GI transit Wireless motility capsule
  Glycaemic control Continuous glucose monitoring
  Circulating inflammatory biomarkers Multiplex analysis of serum samples
  PRO of subjective autonomic symptoms COMPASS-31 questionnaire
Work package III
  Primary outcome Methods of assessment
  Postprandial levels of pancreatic polypeptides Sequential blood sampling during test meal and multiplex 
analysis of serum samples
  Secondary outcomes Methods of assessment
  Postprandial levels of metabolic biomarkers Sequential blood sampling during test meal and multiplex 
analysis of serum samples
  Appetite and satiety sensation Subjective rating on Visual Analogue Scale
  GI transit Wireless motility capsule
  Gallbladder volume Ultrasound
  Resting energy expenditure Indirect calorimetry
  Ad libitum meal response Registration of ingested amount of food
Work package IV
  Primary outcome Methods of assessment
  Patient- reported outcomes of GI symptoms PAGI- SYM and GSRS questionnaire
  Secondary outcomes Methods of assessment
  Cardiovascular and sudomotor function   i) Cardiac vagal tone, ii) Cardiovascular reflexes, iii) Holter 
monitoring, iv) Stimulation of sweat glands in hands and 
feet
  Resting brain electrical activity Electroencephalogram
  Quantitative sensory testing   i) Bone- and muscle pressure, ii) Cold pressor test with 
conditioned pain modulation
  Brain function MRI
Continued
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provides insights to the function of descending inhibitory 
pain pathways.39
Brain imaging and GI tract function
Structural and functional assessments of brain and GI 
tract will be explored by 3 T and 1.5 magnetic resonance 
imaging (Signa HDxt, General Electrics, Milwaukee, 
Wisconsin, USA). Brain networks during rest and concen-
trations of brain metabolites will be investigated by 
functional MRI and magnetic resonance spectroscopy, 
respectively. Stomach volume, adaptive capacity and 
motility, small bowel motility and colonic volume will be 
assessed at regular time points after intake of a 400 mL 
standardised liquid meal (1.5 kcal per mL).
Glycaemic control
Continuous glucose monitoring will be applied in order 
to be able to measure real- time fluctuations in blood 
glucose and estimate ‘Time in Range’. Participants will be 
equipped with the FreeStyle Libre device (Abbot Diabetes 
Care Denmark, Copenhagen Ø, Denmark), which allows 
for continuous glucose monitoring via a portable system 
for 14 days before changing of needle and patch.40
Circulating inflammatory biomarkers
Serum collected from fasting blood samples will be 
aliquoted in appropriate volumes and stored in a biobank 
at −80℃. The complete set of serum samples will be anal-
ysed after study end for levels of inflammatory biomarkers 
such as TNF-α, IL-2, IL-4, IL-6 and IL-10 by multiplexing 
technology.
Gastrointestinal transit
A wireless motility capsule (SmartPill, Given Imaging, 
Yokneam Illit, Israel) will be used to evaluate the whole 
gut transit time as well as segmental for example, stomach, 
small bowel and large bowel transit times. After consump-
tion, the indigestible capsule traverses through the GI 
tract while continuously measuring temperature, pH and 
pressure in the gut lumen.41 Such parameters can be used 
as proxies for the motor function of the enteric nervous 
system.
Postprandial levels of endocrine and metabolic biomarkers
Following an overnight fast, blood samples from partici-
pants in WP- III will be collected at regular intervals during 
the study session. In order to ensure similar glycogen 
storage status and macronutrient balance, participants 
will be instructed to avoid strenuous physical exercise 
and alcohol consumption 48 hours prior to WP- III study 
days. Levels of pancreatic polypeptides and gut hormones 
(gastrin, cholecystokinin, glucose- dependent insulino-
tropic polypeptide, glucagon- like peptide 1 and 2, oxyn-
tomodulin, neurotensin, fibroblast growth factor 19) will 
be assessed after study completion.
Appetite and satiety sensation
Hunger, satiety, fullness and prospective food consump-
tion will be reported by WP- III participants on a Visual 
Analogue Scale at regular time intervals.
Gallbladder volume
Gallbladder emptying will be investigated by volumetric 
measurements using ultrasonography (LOGIQ E9, GE 
Healthcare, Wauesha, Wisconsin, USA).
Resting energy expenditure
Following 30 min of rest, resting energy expenditure will 
be measured for 15 min by resting gas exchange moni-
toring (CCM Express, Indirect Calorimeter, Medgraphics, 
St. Poul, Minnesota, USA).
Ad libitum meal response
In order to assess voluntary food intake, participants in 
WP- III will be provided with an ad libitum pasta Bolog-
nese meal and the ingested amount will be registered.
Randomisation and blinding
Included participants will be allocated a unique anony-
mised identification number kept throughout the entire 
study. Even though path- dependency may exist, we judged 
that a centrally generated block- randomisation list for 
WP- I and WP- II, generated by use of the website www. 
randomization. com was preferable in order to control 
seasonal and geographical bias. The randomisation list 
will be devised by the sponsor and kept in a sealed enve-
lope until last participant last visit in WP- II. Furthermore, 
sealed envelopes, containing treatment allocation for 
each participant, will be kept in a secure location to allow 
for individual unblinding in case of medical emergencies. 
To ensure blinding of the study personnel, sponsor will 
be responsible for assigning active/sham tVNS medical 
devices to study sites. Nevertheless, blinding of partici-
pants and study personnel may be complicated by the fact 
that the sham device is unable to mimic the active stimu-
lation in regard to associated fascial and cervical muscle 
  GI tract function MRI
  Glycaemic control Continuous glucose monitoring
  Circulating inflammatory biomarkers Multiplex analysis of serum samples
  GI transit Wireless motility capsule
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contractions. Therefore, a parallel- group design was 
chosen for WP- I and II. Additionally, to optimise blinding 
of study personnel during WP- I and II, an unblinded and 
otherwise non- involved person at each study site will be 
responsible for the training of participants in the use of 
the tVNS GammaCore device. Furthermore, participants 
will be instructed to restrain from sharing any informa-
tion regarding stimulation and associated physical sensa-
tions to other study personnel.
After completion of WP- I and WP- II, the unblinding of 
treatment allocation will be conducted by the sponsor. 
Likewise, sponsor will prepare a blinded data set divided 
in ‘Treatment A’ and ‘Treatment B’, in order to allow 
for blinding of data analysts. Additionally, the sponsor 
will identify responders of long- term active treatment of 
tVNS (WP- II) for identification of those subjects that are 
eligible for WP- III.
For participants entering WP- III, a new centrally 
generated randomisation code for the order of active/
sham treatment in the cross- over design of WP- III will be 
assigned. Again, study personnel and participants will be 
blinded to the randomisation of treatment order, and 
even though blinding may be complicated, this aspect 
is regarded as acceptable given the fact that the primary 
outcome of WP- III consists of objective measures.
Harms and adverse events
Based on evidence of safety data regarding tVNS from 
previous studies,19 42 we do not expect the intervention 
to cause harm or substantial discomfort for participants. 
Transient side effects during stimulation including short-
ness of breath, hoarseness and twitching of facial muscles, 
are, however, listed as potential adverse reactions to 
GammaCore use (GammaCore User Manual). Further-
more, rare cases of syncope have been reported.43 Partici-
pants experiencing unacceptable levels of side effects will 
be instructed to reduce the level of stimulation intensity.
Adverse events, regardless of severity, will be collected 
regularly during trial conduct and recorded in the case 
report form. Investigators are responsible for imme-
diate (within 24 hours) reporting of any serious adverse 
events to the sponsor. Furthermore, on a yearly basis, 
sponsor will notify relevant authorities of all registered 
serious adverse events. Causality of serious adverse events 
with the intervention will be assessed by a physician, 
and all serious adverse device effects will be reported to 
the manufacturer. Based on interim analyses of serious 
adverse device effects, sponsor will be able to terminate 
the trial if the safety of study participation is considered to 
be insufficient. During participation in the trial, subjects 
are covered by the patient insurance of the respective 
study site.
Sample size calculation
The study is powered to detect a minimal difference of 
30% between the active and the sham tVNS group on 
the GCSI score 1 week (WP- I) or 2 months (WP- II) after 
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(mean±SD),33 60 subjects in each arm are required to 
provide a statistical power of 90% with the use of a two- 
sided significance level of 0.05. A power of 90% was 
chosen in order to account for secondary endpoints. A 
drop- out rate of up to 30% is estimated in the patient 
group. In order to achieve the required sample size, new 
subjects will be mirror randomised to account for partici-
pants withdrawing from the study.
Data collection and data management
Data will be collected by highly experienced research 
personnel, all of which have been trained in the princi-
ples of good clinical practice (GCP). Experimental data 
will be recorded directly and managed on a secure elec-
tronic platform (REDCap Electronic Data Capture Tool, 
hosted at Aalborg University Hospital, Aarhus University, 
and The Capital Region of Denmark). Filled- out question-
naires will be transferred to REDCap by two individual 
entry persons in order to limit the risk of errors in the 
process. Digitalised data are stored for up to 5 years after 
trial end. For each participant, a physical Case Report 
Form, containing all physical source material, will be kept 
in a secure and locked location for 5 years.
Serum samples will be stored at a research biobank for 
a maximum of 10 years. Samples will be anonymised and 
labelled with protocol number, subject randomisation ID 
and date of sample collection.
Monitoring
Monitoring of the trial will be conducted prior to, during 
and after study conduction by the GCP Unit (GCP Unit, 
Aalborg, Aarhus, and Copenhagen, Denmark) in order 
to ensure compliance with study protocol and national 
standards. The monitoring will include complete inspec-
tion of signed informed consent forms and adverse events 
logs. Likewise, investigators and study sites will allow 
for any quality assurance audits by relevant regulatory 
authorities.
Data analysis
The initial analysis of primary outcomes will be by inten-
tion to treat regardless of adherence to study protocol. 
Secondary outcomes will be analysed per protocol, in 
the sense that only subjects, who have completed the 
specific experimental setup, will be included. In WP- I 
and WP- II and WP- III, both primary and secondary 
outcomes will be evaluated as changes from baseline 
by appropriate statistical tests including paired samples 
t- test and equivalent non- parametric tests. Analyses of 
WP- III data will include a linear mixed effects model 
with fixed effects for period and treatment, and random 
effects for sequence and subject nested in sequence. To 
account for multiple testing in the analysis of secondary 
outcomes, the Bonferroni Correction or other appli-
cable corrections will be applied. Missing data will be 
handled by applicable statistical methods including 
multiple imputation. Data collected from drop- outs will 
be included in the data analysis if appropriate (eg, data 
from completed WP- I).
After primary analysis of study specific outcomes, 
the complete anonymised data set will be available for 
Table 5 Time and events of work package IV
  
Screening Work package IV
  Day −5 Day 0 Day 7
Enrolment Informed consent X       
In/exclusion criteria X       
Objective examination X       
Safety outcomes Standard blood samples     X   
Primary outcome GI symptom questionnaires X   X   
Secondary outcomes MRI scan of brain and GI tract   X     
Continuous glucose monitoring     
Holter monitoring       
Sudomotor function     X   
Cardiovascular reflexes     X   
Inflammation markers     X   
Cardiac vagal tone     X   
Resting EEG     X   
QST     X   
GI transit       
Autonomic function questionnaire     X   
EEG, electroencephalography; GI, gastrointestinal; QST, quantitative sensory testing.
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additional analyses by the respective research groups at 
each study site.
Patient and public involvement
The original idea behind the DAN- VNS study was based 
on reports from patients with DAN- induced GI symp-
toms, who requested a simple, safe, and effective treat-
ment option for their condition. The primary objective of 
the study was chosen to be patient- reported outcomes in 
order to put the subjective effect of tVNS in focus rather 
than objective measures, which may not correlate with 
patient evaluation and satisfaction with the treatment. 
After study completion, participants will receive informa-
tion regarding own study arm allocation (active/sham) 
as well as overall findings in the form of a written report. 
Additionally, study results will be disseminated to relevant 
patient associations. No public involvement was included 
in the design phase of the study.
Ethics and dissemination
The study protocol (version 1.4) has been approved by 
the Danish Health and Medicines Authority (CIV-19-07-
029105) and the North Denmark Region Committee on 
Health Research Ethics (N-20190020). Any amendments 
to the protocol will be implemented after approval of 
the mentioned authorities. Sponsor is responsible for 
informing all study sites of any such changes.
The conduction of the study will be in accordance 
with the protocol, the standard “Clinical investigation 
of medical devices for human subjects – Good Clinical 
Practise” (DS/EN ISO 14155:2012), designated Stan-
dard Operating Procedures, any applicable local regula-
tory requirements and laws, as well as the principles of 
the World Medical Association, Declaration of Helsinki 
amended by the 52nd General Assembly, Edinburgh, Scot-
land, October 2000, clarified by the General Assembly in 
Washington 2002, Tokyo 2004, Seoul 2008, and Fortaleza 
2013.
Trial results, positive, negative or inconclusive, will be 
published in relevant international peer- reviewed jour-
nals and presented at national and international confer-
ences. Authorship of published material will be decided 
by the steering committee. Additional dissemination of 
results will be initiated after approval of the principal 
investigator at each study site. Likewise, sponsor may 
grant access to the final data set on request.
DISCUSSION
The strengths of the DAN- VNS study is, that it is a multi-
centre study designed to investigate the hypothesis that 
vagal stimulation will improve GI function in people 
with diabetes with DAN, assessed with sophisticated MRI 
methods to complement the existing knowledge on scin-
tigraphic evaluation.
Limitations
Limitations of the study include the inability to 
verify correct stimulation of the vagal nerve during 
self- administration in WP- I and II. As mentioned above, 
measures such as markings on the neck for correct device 
placement, as well as registration of applied doses in 
patient diaries, have been incorporated in order to limit 
this risk. Another limitation of the study is the lack of 
tVNS treatment in the cohort of healthy controls, which 
could provide novel insights to the effect of vagal stimula-
tion on a healthy and functioning GI tract. However, this 
aspect was decided as being out of the scope of this study, 
but relevant for future studies.
CONCLUSION
With the DAN- VNS study, we expect to provide novel clin-
ical evidence regarding the effect of tVNS for treatment 
of DAN- induced GI symptoms in people with diabetes. 
Furthermore, is it our hope that this knowledge will 
contribute to the introduction of a safe and effective non- 
pharmacological treatment option for this patient group.
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